Current and emerging therapies in primary myelofibrosis

Keyphrases

• Myelofibrosis 100%
• Current Therapies 100%
• Emerging Therapies 100%
• Primary Myelofibrosis 100%
• Constitutional Symptoms 66%
• New Discovery 33%
• Graft-versus-host Disease (GvHD) 33%
• Improved Outcomes 33%
• Mammalian Target of Rapamycin (mTOR) 33%
• High Risk 33%
• Novel Therapies 33%
• Quality of Life 33%
• Hematopoietic Stem Cells 33%
• Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) 33%
• Anemia 33%
• Hydroxyurea 33%
• Androgens 33%
• Targeted Treatment 33%
• Transfusion 33%
• Direct Therapy 33%
• Spleen 33%
• Immunomodulator 33%
• Advanced Age 33%
• Leukocytosis 33%
• Year of Diagnosis 33%
• Transplant-related Mortality 33%
• Median Survival 33%
• Splenomegaly 33%
• Curative Treatment 33%
• JAK2 Inhibitor 33%
• Cytopenia 33%
• Patient Eligibility 33%
• Ineffective Hematopoiesis 33%
• Bone Marrow Fibrosis 33%
• New Targeted Therapy 33%
• Myelogenous Leukemia 33%
• Circulating Blasts 33%
• Alkylator 33%
• Hematopoietic Disorders 33%
• JAK2V617F mutation 33%
• Erythropoietin Analog 33%

Medicine and Dentistry

• Myelofibrosis 100%
• Myeloid metaplasia 100%
• Disease 75%
• Targeted Therapy 50%
• Constitutional Symptoms 50%
• Transplantation 25%
• Quality of Life 25%
• Myeloid Leukemia 25%
• Hydroxyurea 25%
• Cytokine 25%
• Anemia 25%
• Leukocytosis 25%
• Splenomegaly 25%
• Immunomodulating Agent 25%
• Mammalian Target of Rapamycin 25%
• Cytopenia 25%
• Janus Kinase 2 Inhibitor 25%
• Graft Versus Host Reaction 25%
• Janus Kinase 25%
• Androgen 25%
• Erythropoietin 25%
• Hematopoiesis 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Myeloid metaplasia 100%
• Myelofibrosis 100%
• Disease 75%
• Hydroxycarbamide 25%
• Graft Versus Host Reaction 25%
• Cytokine 25%
• Immunomodulating Agent 25%
• Janus Kinase 2 Inhibitor 25%
• Anemia 25%
• Janus Kinase 25%
• Androgen 25%
• Erythropoietin 25%
• Leukocytosis 25%
• Splenomegaly 25%
• Myeloid Leukemia 25%
• Cytopenia 25%